A Phase 2 interventional study of rAvPAL-PEG in Phenylketonuria, sponsored by BioMarin Pharmaceutical. Completed at 14 sites in United States. Open to participants aged 16 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-10-12.
Sponsored by BioMarin Pharmaceutical · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing pegvaliase in Phenylketonurias — 1 open to participants now, 2 under way, 1 of them phase 3. pegvaliase · Phenylketonurias.
Among the 10 studies testing pegvaliase in Phenylketonurias, this one is the 3rd largest by enrollment, is the only one that started in 2010, is one of 4 in phase 2, and was the 3rd registered.
191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.
Browse Phenylketonurias studies →1 of the 10 studies testing pegvaliase in Phenylketonurias is open now, in 1 country. Recruiting first, the newest first:
BioMarin Pharmaceutical · Sites in United States
Ages 18–65
By country, each count listing its studies:
pegvaliase: first FDA approval 2018 (PALYNZIQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.
This study: 16 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2010.
This study's enrollment of 68 is above the median of 27 across 122 interventional studies indexed under Phenylketonurias.
Median enrollment 39 across the 10 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
BioMarin Pharmaceutical is the lead sponsor of 112 studies on the registry; 13 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 12 (63%) have results posted.
35 studies in Phenylketonurias by BioMarin Pharmaceutical: 3 open now, 5 under way, 1 of them phase 3. Of 29 finished, 17 (59%) have results posted.
Among the 35 studies in Phenylketonurias by BioMarin Pharmaceutical, this one is the 11th largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2010, is one of 9 in phase 2, and was the 15th registered.
BioMarin Pharmaceutical’s Phenylketonurias studies by the year they started, since 2004.
1 of the studies testing pegvaliase in Phenylketonurias that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477691BioMarin PharmaceuticalImmune Modulation During Palynziq® Treatment in Adults (IMPALA) | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing pegvaliase in Phenylketonurias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among BioMarin Pharmaceutical’s 35 in Phenylketonurias:
This tab as a report to print or save as PDF → With an account.
This study is an extension of previous rAvPAL-PEG studies. Administration of rAvPAL-PEG will be continued to assess whether long-term dosing of rAvPAL-PEG is safe and can maintain reduced blood Phe concentrations in PKU subjects.
PAL-003 is designed to evaluate long-term treatment of subjects who are continuing to take rAvPAL-PEG. Subjects'previous rAvPAL-PEG dosing will continue in PAL-003. In PAL-003, each subject's dose will be adjusted as needed to attain or maintain blood Phe concentrations of 60-600 µmol/L. rAvPAL-PEG dose will be based on either a subject's weight or will be a fixed dose (subjects who have maintained blood Phe levels to 60-600 µmol/L for at least 2 consecutive weeks and who have maintained a stable rAvPAL-PEG dose for at least 2 consecutive weeks). Doses will be evaluated on an individual basis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
rAvPAL-PEG in varying doses dependent on safety and efficacy.
Drug: rAvPAL-PEG
The doses are planned to be in the same range as those tested in PAL-002 or PAL-004 and then modified either by increasing or decreasing the dose, adhering to an upper limit up to 5.0 mg/kg per week or 375 mg/week, considering each subject's individual responses related to safety and efficacy.
Also known as: Pegvaliase
Change From Baseline in the Blood Phenylalanine (Phe) Concentration
Blood Phe Concentration (Change from Baseline) and Daily Dose in PAL-003 Subjects by Disposition (PAL-003 Population)
Time frame: At Baseline and Change from Baseline to Week 48, Week 96, Week 144, Week 216, and Week 240
Pharmacokinetics-Plasma Pegvaliase Concentration
Steady-state Pharmacokinetics (PK) of pegvaliase was measured in subjects who have achieved and maintained target blood Phe
Time frame: At Baseline, Week 48, Week 96, Week 144, Week 216 and Week 240
Number of Subjects With Treatment Emergent Adverse Events (TEAEs)
A treatment-emergent AE was defined as any adverse event (AE) newly appearing or worsened in severity following initiation of study drug until 4 weeks after last dose of pegvaliase (PAL-003)
Time frame: Up to 109 months.
Percentage of Participants With Positive PEG IgG Antibody
The presence of IgG Antibodies against PEG (polyethylene glycol) is measured overtime
Time frame: At Baseline and Change from Baseline to Week 24, Week 52, Week 104 and Week 156
Percentage of Participants With Positive PAL IgG Antibody
The presence of IgG Antibodies against PAL (phenylalanine ammonia lyase) is measured overtime
Time frame: At Baseline and Change from Baseline to Week 24, Week 52, Week 104 and Week 156
This was a multicenter study, conducted in 14 study centers of United States.
| Milestone | rAvPAL-PEG |
|---|---|
| Started | 68 |
| Completed | 46 |
| Not completed | 22 |
| Withdrew: Withdrawal by subject | 11 |
| Withdrew: Physician decision | 5 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Adverse event | 2 |
| Withdrew: Withdrawal by sponsor | 1 |
Blood Phe Concentration (Change from Baseline) and Daily Dose in PAL-003 Subjects by Disposition (PAL-003 Population)
| μmol/L | rAvPAL-PEG |
|---|---|
| Baseline | 1022.4 ± 530.39 |
| Change from Baseline to Week 48 | -553.5 ± 652.95 |
| Change from Baseline to Week 96 | -653.3 ± 637.81 |
| Change from Baseline to Week 144 | -672.3 ± 621.06 |
| Change from Baseline to Week 216 | -535.9 ± 573.08 |
| Change from Baseline to Week 240 | -574.9 ± 549.90 |
Steady-state Pharmacokinetics (PK) of pegvaliase was measured in subjects who have achieved and maintained target blood Phe
| ng/mL | rAvPAL-PEG |
|---|---|
| At Baseline | 961.5 ± 3013.43 |
| Week 48 | 4127.3 ± 6116.72 |
| Week 96 | 7457.7 ± 10685.02 |
| Week 144 | 7196.1 ± 11678.89 |
| Week 216 | 7764.4 ± 9292.34 |
| Week 240 | 6557.8 ± 9220.95 |
A treatment-emergent AE was defined as any adverse event (AE) newly appearing or worsened in severity following initiation of study drug until 4 weeks after last dose of pegvaliase (PAL-003)
| Participants | rAvPAL-PEG |
|---|---|
| Subjects with any adverse event | 68 |
| Subjects with any serious adverse events | 12 |
| Subjects with any treatment-related adverse event | 65 |
| Any treatment-related serious adverse event | 6 |
| Death | 0 |
The presence of IgG Antibodies against PEG (polyethylene glycol) is measured overtime
| Participants | rAvPAL-PEG |
|---|---|
| Baseline | 29 |
| Change from Baseline to Week 24 | 24 |
| Change from Baseline to Week 52 | 14 |
| Change from Baseline to Week 104 | 2 |
| Change from Baseline to Week 156 | 7 |
The presence of IgG Antibodies against PAL (phenylalanine ammonia lyase) is measured overtime
| Participants | rAvPAL-PEG |
|---|---|
| Baseline | 10 |
| Change from Baseline to Week 24 | 63 |
| Change from Baseline to Week 52 | 60 |
| Change from Baseline to Week 104 | 48 |
| Change from Baseline to Week 156 | 45 |
Collected over Up to 109 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| rAvPAL-PEG | 0/68 (0%) | 12/68 (17.6%) | 68/68 (100%) |
| Event | rAvPAL-PEG |
|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 2/68 |
| HypersensitivityImmune system disorders | 1/68 |
| Abortion inducedSurgical and medical procedures | 1/68 |
| Anaphylactic reactionImmune system disorders | 1/68 |
| AppendicitisInfections and infestations | 1/68 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/68 |
| BacteraemiaInfections and infestations | 1/68 |
| Bacterial infectionInfections and infestations | 1/68 |
| Bone marrow failureBlood and lymphatic system disorders | 1/68 |
| Diarrhoea infectiousInfections and infestations | 1/68 |
| Event | rAvPAL-PEG |
|---|---|
| NasopharyngitisInfections and infestations | 45/68 |
| HeadacheNervous system disorders | 43/68 |
| RashSkin and subcutaneous tissue disorders | 38/68 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 37/68 |
| Injection site reactionGeneral disorders | 36/68 |
| Injection site erythemaGeneral disorders | 36/68 |
| Injection site bruisingGeneral disorders | 34/68 |
| Upper respiratory tract infectionInfections and infestations | 34/68 |
| UrticariaSkin and subcutaneous tissue disorders | 33/68 |
| CoughRespiratory, thoracic and mediastinal disorders | 33/68 |
All Enrolled Subjects
| Age, Continuous(years) | rAvPAL-PEG |
|---|---|
| Mean | 28.31 ± 8.66 |
| Sex: Female, Male(Participants) | rAvPAL-PEG |
|---|---|
| Female | 40 |
| Male | 28 |
| Ethnicity (NIH/OMB)(Participants) | rAvPAL-PEG |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 67 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | rAvPAL-PEG |
|---|---|
| American Indian or Alaska Native | 1 |
| White | 66 |
| Asian | 1 |
| Weight(kg) | rAvPAL-PEG |
|---|---|
| Mean | 83.0 ± 26.39 |
| Body mass index (BMI)(kg/m^2) | rAvPAL-PEG |
|---|---|
| Mean | 29.2 ± 8.44 |
| Baseline blood Phe(μmol/L) | rAvPAL-PEG |
|---|---|
| Mean | 1022.4 ± 530.39 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2010 to primary completion in Jan 2019, 108 months.
Results were first posted in Oct 2021, 2 years 8 months after primary completion. A results delay was requested in Dec 2019.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegvaliase